肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
临床试验招募
登录/注册
VIP特权
广告
广告加载中...

文章:

孤立性胸膜播散型肺癌:一种潜在的循环肿瘤DNA非释放性肿瘤类型

Lung Cancer with Isolated Pleural Dissemination as a Potential ctDNA Non-Shedding Tumor Type

原文发布日期:30 July 2025

DOI: 10.3390/cancers17152525

类型: Article

开放获取: 是

 

英文摘要:

Objectives:Circulating tumor DNA (ctDNA) has emerged as a reliable prognostic biomarker in both early- and late-stage non-small cell lung cancer (NSCLC) patients. However, its role in NSCLC with pleural dissemination (M1a), a subset of disease with indolent biology, remains to be elucidated.Methods:We collected 41 M1a patients with serial ctDNA and CEA monitoring. Progression-free survival (PFS) was assessed between patients with different levels of ctDNA and CEA. An independent cohort of 61 M1a patients was included for validation.Results:At the diagnostic landmark, the detection rates for ctDNA and CEA were 22% and 55%, respectively. Among patients who experienced disease progression with pleural metastases, only ten had detectable ctDNA in longitudinal timepoints, resulting in a sensitivity of 50%. Moreover, there was no significant difference in PFS between patients with longitudinally detectable and undetectable ctDNA (HR: 0.86, 95% CI 0.33–2.23,p= 0.76). In contrast, patients with a decreasing CEA trend within 3 months after diagnosis were associated with an improved PFS (HR: 0.22; 95% CI, 0.03–1.48,p= 0.004). This finding is confirmed in an independent M1a patient cohort.Conclusions:Together, our findings suggest that M1a NSCLC with isolated pleural dissemination may represent a “non-shedding” tumor type, where ctDNA shows limited diagnostic and prognostic value. Monitoring early changes in CEA could be a more cost-effective predictor of disease progression.

 

摘要翻译: 

目的:循环肿瘤DNA(ctDNA)已成为早期和晚期非小细胞肺癌(NSCLC)患者可靠的预后生物标志物。然而,其在具有惰性生物学特征的胸膜播散型(M1a)NSCLC中的作用仍有待阐明。 方法:本研究纳入41例M1a期患者,进行连续ctDNA与癌胚抗原(CEA)监测。通过比较不同ctDNA与CEA水平患者的无进展生存期(PFS)进行评估,并纳入61例M1a患者组成独立队列进行验证。 结果:在诊断时间点,ctDNA与CEA的检出率分别为22%和55%。在发生胸膜转移进展的患者中,仅10例在纵向时间点检测到ctDNA,灵敏度为50%。此外,纵向可检测与未检测到ctDNA患者的PFS无显著差异(风险比:0.86,95%置信区间0.33–2.23,p=0.76)。相比之下,诊断后3个月内CEA呈下降趋势的患者PFS显著改善(风险比:0.22;95%置信区间0.03–1.48,p=0.004)。该发现在独立M1a患者队列中得到验证。 结论:本研究提示,单纯胸膜播散的M1a期NSCLC可能属于"低释放"肿瘤类型,ctDNA的诊断与预后价值有限。监测CEA的早期变化可能是更具成本效益的疾病进展预测指标。

 

 

原文链接:

Lung Cancer with Isolated Pleural Dissemination as a Potential ctDNA Non-Shedding Tumor Type

广告
广告加载中...